30个月完全缓解作为一线滤泡性淋巴瘤治疗的替代终点:多项随机试验的个体患者水平分析
该研究基于1990年后发表的13项随机多中心试验的个体患者数据,评估一线滤泡性淋巴瘤诱导治疗后30个月完全缓解率(CR30)能否作为无进展生存期(PFS)的替代终点。共分析8项诱导试验和5项维持试验的3837例可评估患者,CR30比值比与PFS风险比的线性回归R²WLS为0.88(95%CI 0.77-0.96),双变量copula模型R²Copula为0.86(95%CI 0.72-1.00),均达到预设替代阈值。CR30较对照50%绝对提高至少11%可预测PFS的显著治疗效应(风险比0.69)。
要点
- CR30与PFS治疗效应相关,R²WLS为0.88(95%CI 0.77-0.96),R²Copula为0.86(95%CI 0.72-1.00),达到预设替代标准。
- CR30较对照50%绝对提高至少11%可预测PFS的显著治疗效应(风险比0.69)。
- CR30作为替代终点可能加速一线滤泡性淋巴瘤治疗试验的药物开发。
核心结论
- 这项大型前瞻性汇总分析表明,CR30是一线滤泡性淋巴瘤治疗试验中PFS的替代终点,使用该终点可能加速治疗开发,使新疗法在PFS结果成熟前数年惠及患者。
研究设计与样本
- 分析1990年后发表的13项随机多中心诱导和维持治疗试验的个体患者数据,共3837例可评估患者,其中8项诱导试验和5项维持试验。
- 通过线性回归(R²WLS)和双变量copula(R²Copula)模型评估CR30比值比与PFS风险比的相关性。
- 预设替代标准要求R²WLS或R²Copula≥0.80,且95%CI下限>0.60。
主要发现
- 预设替代阈值达到:R²WLS为0.88(95%CI 0.77-0.96),R²Copula为0.86(95%CI 0.72-1.00)。
- 多项敏感性和补充分析支持结果的稳健性。
- CR30较对照50%绝对提高至少11%可预测PFS的显著治疗效应(风险比0.69)。
关键数值与推荐
- 预设替代标准:R²WLS或R²Copula≥0.80,且95%CI下限>0.60。
- CR30较对照50%绝对提高至少11%可预测PFS的显著治疗效应(风险比0.69)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Follicular lymphoma (FL) is an indolent cancer, with effective but rarely curative treatment options. As a standard study end point for first-line FL therapy, progression-free survival (PFS) requires extended follow-up (median PFS, > 7 years). To provide patients with earlier access to newer therapies, an earlier end point to expedite clinical trials is needed. Our objective was to formally assess the complete response rate at 30 months (CR30) after initiation of induction therapy as a potential surrogate end point for PFS in first-line FL therapy. Patients and Methods We analyzed individual patient data from 13 randomized multicenter trials of induction and maintenance regimens in first-line FL therapy published after 1990 and with sufficient data to evaluate whether CR30 could predict treatment effects on PFS. Correlation of the CR30 odds ratio with the PFS hazard ratio was evaluated by both linear regression (R2WLS) and bivariate copula (R2Copula) models. Prespecified criteria for surrogacy required either R2WLS or R2Copula ≥ 0.80, with a lower-bound 95% CI > 0.60. Results Data from eight induction and five maintenance randomized trials in 3,837 evaluable patients were analyzed. The prespecified surrogacy threshold was met, with an R2WLS of 0.88 (95% CI, 0.77 to 0.96) and an R2Copula of 0.86 (95% CI, 0.72 to 1.00). Multiple sensitivity and supplemental analyses supported the robustness of the findings. A minimum 11% absolute improvement in CR30 from a 50% control rate predicted a significant treatment effect on PFS (hazard ratio, 0.69). Conclusion This large, prospective, pooled analysis of randomized chemotherapy, immunotherapy, and chemoimmunotherapy trials demonstrates that CR30 is a surrogate end point for PFS in first-line FL treatment trials. Use of this end point may expedite therapeutic development with the intent of bringing novel therapies to this patient population years before PFS results are mature.
引用
- Shi Q, Flowers CR, Hiddemann W, et al. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. J Clin Oncol. 2016. PMID: 28029309. doi:10.1200/JCO.2016.70.8651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。